Midas ShaScancell Britain is widely recognised as a healthcare powerhouse with firms champing at the bit to produce blockbuster sales. Many are in the cancer field. Despite the hype around Ozempic, the market for cancer drugs is at least three times bigger than its weight-loss counterpart and expected to remain so for years. Already generating sales of almost £175billion a year, revenues from cancer treatments are forecast to more than double this decade and carry on rising thereafter. That leaves room for plenty of blockbusters and Scancell is hoping to create one of them. Founded by immunologist Professor Lindy Durrant, the company is developing a cure for advanced skin cancer and early signs are highly encouraging. The treatment combines a vaccine developed by Durrant and her team with two widely available drugs. Trials to date have shown an 85 per cent success rate, far outweighing alternative approaches and better than Durrant ever imagined. Vaccines are usually associated with disease prevention, from smallpox to measles to Covid. Cancer vaccines are different. They aim to stimulate the body's immune system so that it produces cells that will fight and destroy cancer tumours. Researchers have been trying to develop an effective vaccine for years but cancer keeps outwitting them. Durrant's Eureka moment came when she decided to try a combination approach, blending her immune-system-boosting vaccine with drugs that allow the medicine to enter tumorous cells and do their magic. The treatment has already proved successful on a small group of patients. A larger trial will be ready by the end of this year and further studies are expected thereafter. Drug trials can take years but Durrant should be able to move faster, as her treatment could prove a lifesaver. There is also the possibility of moving into other forms of cancer, which could help millions of people worldwide. Existing cancer treatments tend to be extremely expensive, riddled with side-effects or both. Scancell's therapy is simple to make, easier on the body than alternatives and a lot cheaper too. Midas verdict: Scancell shares, which are listed on the junior AIM market, are less than 12p today. The company has been through tough times and nothing is certain in the world of drug research. But Durrant has more than 40 years' experience in the cancer field. She is a renowned professor at Nottingham University and believes she is on to a winner. If she is right, Scancell could fly - and that makes the shares well worth considering.re Tips, again . . .17 Jul 2024 09:49
Marcus 9762 over there yesterday, posted the subscribers script from 'This is Money' in the Daily Mail'. The article still seems to be current today. Worth a repeat hopefully . . . . .
"Scancell - Britain is widely recognised as a healthcare powerhouse with firms champing at the bit to produce blockbuster sales. Many are in the cancer field. Despite the hype around Ozempic, the market for cancer drugs is at least three times bigger than its weight-loss counterpart and expected to remain so for years.
Already generating sales of almost £175billion a year, revenues from cancer treatments are forecast to more than double this decade and carry on rising thereafter. That leaves room for plenty of blockbusters and Scancell is hoping to create one of them. Founded by immunologist Professor Lindy Durrant, the company is developing a cure for advanced skin cancer and early signs are highly encouraging. The treatment combines a vaccine developed by Durrant and her team with two widely available drugs. Trials to date have shown an 85 per cent success rate, far outweighing alternative approaches and better than Durrant ever imagined.
Vaccines are usually associated with disease prevention, from smallpox to measles to Covid. Cancer vaccines are different. They aim to stimulate the body's immune system so that it produces cells that will fight and destroy cancer tumours.
Researchers have been trying to develop an effective vaccine for years but cancer keeps outwitting them. Durrant's Eureka moment came when she decided to try a combination approach, blending her immune-system-boosting vaccine with drugs that allow the medicine to enter tumorous cells and do their magic.
The treatment has already proved successful on a small group of patients. A larger trial will be ready by the end of this year and further studies are expected thereafter. Drug trials can take years but Durrant should be able to move faster, as her treatment could prove a lifesaver. There is also the possibility of moving into other forms of cancer, which could help millions of people worldwide.
Existing cancer treatments tend to be extremely expensive, riddled with side-effects or both. Scancell's therapy is simple to make, easier on the body than alternatives and a lot cheaper too.
Midas verdict: Scancell shares, which are listed on the junior AIM market, are less than 12p today. The company has been through tough times and nothing is certain in the world of drug research. But Durrant has more than 40 years' experience in the cancer field. She is a renowned professor at Nottingham University and believes she is on to a winner. If she is right, Scancell could fly - and that makes the shares well worth considering."
Thanks Marcus.
Sign In
Follow the stocks
